Clinical trials: CONTROL Condition
Mitochondrial Myopathy
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate…
- Trial name
- MMPOWER (NCT02367014)
- Testing
- elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose)
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Stealth BioTherapeutics Inc.
Osteoarthritis, Knee, Musculoskeletal Diseases
A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee
This clinical study is to evaluate the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic knee osteoarthritis (OA).
- Trial name
- NCT00131352
- Testing
- hylan G-F 20, Phosphate Buffered Saline
- Where
- 21 sites in Belgium, Czechia and 4 more
- Volunteers
- 253 people
- Sponsor
- Genzyme, a Sanofi Company
Nondependent Opioid Abuse, Episodic
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to…
- Trial name
- NCT01380093
- Testing
- MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19-Induced Parosmia
Stellate Ganglion Block for COVID-induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.
- Trial name
- SGB (NCT06253806)
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- NURTURE 1 (NCT01350804)
- Testing
- AIN457, Abatacept
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal…
- Trial name
- BELLE-2 (NCT01610284)
- Testing
- Fulvestrant, BKM120
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control…
- Trial name
- SUSTAIN (NCT03061214)
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin
- Where
- 67 sites in Brazil, China and 5 more
- Volunteers
- 868 people
- Sponsor
- Novo Nordisk A/S
Acne Vulgaris
Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion…
- Trial name
- NCT03717506
- Testing
- GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
- Where
- 34 sites in United States
- Volunteers
- 1,236 people
- Sponsor
- Balmoral Medical company
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hepatic Encephalopathy
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
- Trial name
- NCT00298038
- Testing
- Rifaximin
- Volunteers
- 299 people
- Sponsor
- Bausch Health Americas, Inc.
Otitis Media With Effusion
OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement
The purpose of this study is to confirm the effectiveness, safety and tolerability of OTO-201 in the treatment of pediatric subjects with bilateral middle ear effusion who require tympanostomy tube placement.
- Trial name
- NCT01949155
- Testing
- OTO-201
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Otonomy, Inc.
Sensorineural Hearing Loss, Noise Induced Hearing Loss
FX-322 in Adults With Stable Sensorineural Hearing Loss
This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.
- Conditions
- Sensorineural Hearing Loss, Noise Induced Hearing Loss, Sudden Sensorineural Hearing Loss
- Trial name
- NCT04120116
- Testing
- FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses)
- Where
- 16 sites in United States
- Volunteers
- 95 people
- Sponsor
- Frequency Therapeutics
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
- Trial name
- NCT04553406
- Testing
- SPR720, Open-label Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Spero Therapeutics
Fibromyalgia
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia.
- Trial name
- NCT01271933
- Testing
- pregabalin
- Where
- 52 sites in United States, Canada and 2 more
- Volunteers
- 441 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Nasal Polyposis
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
This is a phase 2 study to evaluate multiple doses of AK001 across 2 active doses. Pharmacodynamic activity will also be evaluated.
- Trial name
- NCT02734849
- Testing
- AK001 low dose, AK001 high dose
- Where
- 15 sites in United States, Belgium and 4 more
- Volunteers
- 40 people
- Sponsor
- Allakos Inc.
Atopic Dermatitis, Skin Diseases
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different…
- Conditions
- Atopic Dermatitis, Skin Diseases, Eczema
- Trial name
- BRONTE (NCT04818138)
- Testing
- Narrowband UVB phototherapy, Broadband UVB phototherapy
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- Women's College Hospital
Pain, Post-operative
Serratus Anterior Plane Block in Patients Undergoing Mastectomy
This is a randomized, interventional prospective study. Patients (n=66) undergoing mastectomies with or without tissue expander will be randomized to receive a supra-serratus or sub-serratus regional plane block prior to surgery.
- Trial name
- NCT03154658
- Testing
- Ropivacaine 0.35%
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Texas Southwestern Medical Center
Hiv, Minority Stress
Developing an Online Mindfulness-based Intervention to Reduce Minority Stress and HIV Risk Among Young Adult MSM - Aim 3
The overall aim of the research study is to develop and test a mindfulness-based program for young adult gay, bisexual, and queer men at risk for HIV (Brown University IRB approved protocol #2004002698).
- Conditions
- Hiv, Minority Stress, Mental Health Wellness 1
- Trial name
- MBQR (NCT05855655)
- Testing
- Mindfulness-Based Queer Resilience (MBQR)
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Brown University
Rheumatoid Arthritis, Arthritis
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
- Conditions
- Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases
- Trial name
- RESOLUTION-1 (NCT05516758)
- Testing
- Peresolimab
- Where
- 131 sites in United States, Argentina and 9 more
- Volunteers
- 491 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.